Sulfotransferase 1A1 (SULT1A1) Genotype and Phenotype in Relation to Efficacy of Tamoxifen Treatment
Abstract
Genetic polymorphisms in SULT1A1 have been associate overall survival in breast cancer patients receiving tamoxifen. Studies have suggested that exposure of a breast cancer cell line to 4-hydroxytamoxifen (4-OH TAM) results in the, upregulation of SULT1A1 of transcript may be related to the observed difference in overall survival by SULT1A1 genotype in tamoxifen-treated patients. SULT1A1 is expressed in platelets, and its expression has been shown to be coordinately regulated across tissues. Therefore, we proposed to recruit 150 patients with primary, incident breast cancer and collect a blood sample for platelet isolation and SULT1A1 activity as says both before and after tamoxifen treatment. Forty-nine patients have been recruited to date, and platelets, along with other blood components have been stored for additionally, the effect of 4-OH TAM treatment on the breast cancer cell lines MCF-7 and ZR74-1 have been evaluated by RT-PCR. Analysis by this method did not support the idea that SULT1A1 was regulated by tamoxifen. When enzymatic activity assays were performed using cytosol from cells treated with 4-OH TAM, there was no evidence of increased enzymatic activity with this treatment. These investigations will continue with other breast cancer cell lines.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2003
- Accession Number
- ADA421960
Entities
People
- Susan A. Nowell
Organizations
- University of Arkansas for Medical Sciences